Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review

Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have revolutionized the standard treatment for EGFR T790M-positive non-small cell lung cancer (NSCLC). Osimertinib is one of the third-generation EGFR-TKIs and is currently the most advanced in clinical develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Longqiu, Zhong, Wenjuan, Li, An, Qiu, Zhengang, Xie, Ruilian, Shi, Huaqiu, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263887/
https://www.ncbi.nlm.nih.gov/pubmed/34350265
http://dx.doi.org/10.21037/atm-21-2823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263887/
https://www.ncbi.nlm.nih.gov/pubmed/34350265
http://dx.doi.org/10.21037/atm-21-2823

Ejemplares similares